Sentinel Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Sentinel Asset Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-57,477	Closed	-$12.8M	–	17
2017 Q3	$12.8M	Hold	57,477	–	–	0.31%	143
2017 Q2	$13M	Sell	57,477 -4,800	-8%	-$1.05M	0.31%	138
2017 Q1	$12.4M	Sell	62,277 -3,663	-6%	-$706K	0.29%	129
2016 Q4	$12M	Sell	65,940 -9,859	-13%	-$1.68M	0.3%	103
2016 Q3	$12.4M	Hold	75,799	–	–	0.3%	127
2016 Q2	$10.8M	Buy	75,799 +3,476	+5%	+$496K	0.26%	142
2016 Q1	$9.89M	Sell	72,323 -31,287	-30%	-$4.11M	0.22%	141
2015 Q4	$14.4M	Buy	103,610 +6,200	+6%	+$859K	0.36%	90
2015 Q3	$13.1M	Buy	97,410 +2,570	+3%	+$370K	0.33%	100
2015 Q2	$14.3M	Buy	94,840 +12,390	+15%	+$1.77M	0.33%	113
2015 Q1	$11.1M	Sell	82,450 -97,050	-54%	-$12M	0.24%	147
2014 Q4	$21.6M	Sell	179,500 -4,320	-2%	-$497K	0.45%	86
2014 Q3	$20.8M	Buy	183,820 +53,850	+41%	+$6.38M	0.43%	87
2014 Q2	$15.6M	Buy	129,970 +310	+0.2%	+$37.9K	0.31%	131
2014 Q1	$16.6M	Buy	+129,660	New	+$16.6M	0.33%	130

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HCM

Hitchwood Capital Management New York $184M AUM 3.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Sentinel Asset Management's BIO Position: Q4 2017 in Review

Sentinel Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2017, closing a stake of 57,477 shares — an estimated $12.8M sold.

Sentinel Asset Management first reported a position in BIO in Q1 2014 and held it in 15 quarters. The position peaked at $21.6M in Q4 2014. 302 funds tracked by Wall St. Rank hold BIO as of Q4 2017.

Sentinel Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2017 after selling out during the quarter.
Sentinel Asset Management sold 57,477 Bio-Rad Laboratories Class A shares in Q4 2017, an estimated $12.8M.
Sentinel Asset Management first reported a position in Bio-Rad Laboratories Class A in Q1 2014 and held it in 15 quarters.
Sentinel Asset Management's Bio-Rad Laboratories Class A position peaked at $21.6M in Q4 2014.
302 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2017.

Based on Sentinel Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.